Missed Sandoz Group's Rally? What Holders Had To Believe

If Sandoz Group sat on your watchlist instead of in your portfolio, the result may feel painful. For Sandoz Group shareholders, the return over the past year was 58.3%, including dividends. That jump invites a simple question. Back on 19 October 2025, when bullish and bearish analysts argued over biosimilar growth, what specific assumption about rising healthcare demand and aging populations could have helped you judge whether Sandoz’s push to accelerate biosimilar adoption was being underappreciated?

The easy part of this move is behind Sandoz Group. Zero in on 198 high quality undervalued stocks for companies trading below our estimates.

The Argument Sandoz Investors Were Really Weighing

The shares cost CHF48.42 at the start of the period, and you were effectively choosing between two different stories about where Sandoz Group might head next.

The bullish narrative treated a Fair Value of CHF60.37, the price implied if its brighter assumptions played out, as reasonable and leaned on 8.9% annual revenue growth and a profit margin rising toward 15.3% within about three years.

The cautious narrative used a Fair Value of CHF38.02 and focused on 4.5% revenue growth, an 11.0% margin, and the risk that US tariffs and pricing pressure would keep biosimilar economics tight.

What The Sandoz Evidence Actually Tested

Sandoz Group’s push to expand its biosimilar portfolio through deals with Henlius and mAbxience, along with Brazil approval for Owozy, lined up with the bullish case that aging populations and healthcare cost pressure could support higher biosimilar volumes. The same period produced mixed scorecards, however. Revenue reached US$5,784m in H1 2026, while net income fell to US$109m and net margin slipped to 1.9%. The evidence cut both ways.

The lesson is simple. When a story hinges on rising demand and better economics, do not just track sales. Watch whether net margin moves toward the forecast level and whether each new product or partnership shows up in that profitability line.

What Sandoz Group’s Price Already Assumes

Sandoz Group now trades at CHF76.58, after a 58.3% gain over the past year. The selected Narrative’s Fair Value estimate sits below that level, even while acknowledging the company’s push in biosimilars, manufacturing expansion in Slovenia, and new products like Sandoz Semaglutide.

A buyer today is effectively assuming that execution on biosimilar launches and new capacity supports resilient earnings. The question from the selected Narrative is how rising pricing pressure, regulatory complexity, and higher fixed costs might challenge that assumption.

"Ongoing and rising global pressure on drug pricing, compounded by newly confirmed US tariffs on EU generics and biosimilars, is likely to further constrain Sandoz's ability to drive top-line revenue growth and will place significant downward pressure on net margins going forward."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Which Company Could Surprise You Next?

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 43% below our estimate - sells hardware agnostic oncology software that hospitals adopt for AI guided planning.
• Company 2 - 46% below our estimate - leans into new flagship locations and digital sales as licensing income declines.
• Company 3 - 28% below our estimate - uses cash from an operating mine to drill nearby targets for potential expansion.

That is three of the list. See the full list of 202 financially solid companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com